ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

eXoZymes Inc. - Common Stock (NQ:EXOZ)

9.800 +0.180 (+1.87%)

Streaming Delayed Price Updated: 3:48 PM EDT, May 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,481
Open	10.12
Bid (Size)	9.750 (500)
Ask (Size)	15.76 (200)
Prev. Close	9.620
Today's Range	9.800 - 10.12
52wk Range	7.080 - 18.40
Shares Outstanding	8,387,250
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

May 07, 2026

Via ACCESS Newswire

eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast

April 10, 2026

Via ACCESS Newswire

Performance

YTD	-10.8%	-10.8%
1 Month	-14.8%	-14.8%
3 Month	-6.0%	-6.0%
6 Month	-38.7%	-38.7%
1 Year	-21.9%	-21.9%

More News

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

March 31, 2026

Via ACCESS Newswire

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

March 25, 2026

Via ACCESS Newswire

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

March 18, 2026

Via ACCESS Newswire

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

March 12, 2026

Via ACCESS Newswire

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

February 10, 2026

Via ACCESS Newswire

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

January 29, 2026

Via ACCESS Newswire

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

December 11, 2025

Via ACCESS Newswire

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

November 13, 2025

Via ACCESS Newswire

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

November 13, 2025

Via ACCESS Newswire

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

November 10, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 31, 2025

Via Benzinga

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference

October 30, 2025

Via ACCESS Newswire

CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference

October 29, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 24, 2025

Via Benzinga

CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference

October 23, 2025

Via ACCESS Newswire

Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees

September 30, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

August 12, 2025

Via ACCESS Newswire

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

August 07, 2025

Via ACCESS Newswire

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

July 29, 2025

Via ACCESS Newswire

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

July 22, 2025

Via ACCESS Newswire

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

June 26, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is eXoZymes Inc. - Common Stock publicly traded?

Yes, eXoZymes Inc. - Common Stock is publicly traded.

What exchange does eXoZymes Inc. - Common Stock trade on?

eXoZymes Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for eXoZymes Inc. - Common Stock?

The ticker symbol for eXoZymes Inc. - Common Stock is EXOZ on the Nasdaq Stock Market

What is the current price of eXoZymes Inc. - Common Stock?

The current price of eXoZymes Inc. - Common Stock is 9.800

When was eXoZymes Inc. - Common Stock last traded?

The last trade of eXoZymes Inc. - Common Stock was at 05/11/26 03:48 PM ET

What is the market capitalization of eXoZymes Inc. - Common Stock?

The market capitalization of eXoZymes Inc. - Common Stock is 82.20M

How many shares of eXoZymes Inc. - Common Stock are outstanding?

eXoZymes Inc. - Common Stock has 82M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.